[go: up one dir, main page]

MX2018004175A - Derivado oxa espiro, su metodo de preparacion, y sus aplicaciones en medicinas. - Google Patents

Derivado oxa espiro, su metodo de preparacion, y sus aplicaciones en medicinas.

Info

Publication number
MX2018004175A
MX2018004175A MX2018004175A MX2018004175A MX2018004175A MX 2018004175 A MX2018004175 A MX 2018004175A MX 2018004175 A MX2018004175 A MX 2018004175A MX 2018004175 A MX2018004175 A MX 2018004175A MX 2018004175 A MX2018004175 A MX 2018004175A
Authority
MX
Mexico
Prior art keywords
applications
preparation
medicines
method therefor
spiro derivative
Prior art date
Application number
MX2018004175A
Other languages
English (en)
Other versions
MX382815B (es
Inventor
Sun Piaoyang
He Feng
Chen Yang
Tao Weikang
Li Xin
He Mingxun
Liu Tao
Feng Binqiang
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2018004175A publication Critical patent/MX2018004175A/es
Publication of MX382815B publication Critical patent/MX382815B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con un derivado oxa espiro, un método de preparación del mismo, y aplicaciones del mismo en medicinas. Particularmente, la presente invención se relaciona con un derivado oxa espiro representado por la fórmula (I), un método de preparación del mismo, y una composición farmacéutica que comprende el derivado, las aplicaciones del mismo como un agonista del receptor MOR, y aplicaciones en la preparación de fármacos para tratar y/o evitar los dolores y los dolores relacionados con las enfermedades. Los grupos de sustitución en la fórmula (I) son los mismos que las definiciones en la especificación.
MX2018004175A 2015-10-15 2016-09-30 Derivado oxa espiro, su metodo de preparacion, y sus aplicaciones en medicinas. MX382815B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510665328 2015-10-15
CN201511032876 2015-12-31
PCT/CN2016/101064 WO2017063509A1 (zh) 2015-10-15 2016-09-30 氧杂螺环类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
MX2018004175A true MX2018004175A (es) 2018-06-06
MX382815B MX382815B (es) 2025-03-12

Family

ID=58517778

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004175A MX382815B (es) 2015-10-15 2016-09-30 Derivado oxa espiro, su metodo de preparacion, y sus aplicaciones en medicinas.

Country Status (16)

Country Link
US (1) US10442793B2 (es)
EP (1) EP3354649B1 (es)
JP (1) JP6824502B2 (es)
KR (1) KR102703513B1 (es)
CN (1) CN107001347B (es)
AU (1) AU2016339404B2 (es)
CA (1) CA3000761C (es)
DK (1) DK3354649T3 (es)
ES (1) ES2772689T3 (es)
HU (1) HUE048032T2 (es)
MX (1) MX382815B (es)
PL (1) PL3354649T3 (es)
PT (1) PT3354649T (es)
RU (1) RU2733373C2 (es)
TW (1) TWI727981B (es)
WO (1) WO2017063509A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018188643A1 (zh) * 2017-04-14 2018-10-18 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的盐、其富马酸盐i晶型及制备方法
BR112019020691A2 (pt) * 2017-04-14 2020-05-12 Jiangsu Hengrui Medicine Co., Ltd. Composição farmacêutica contendo agonista do mor e agonista do kor, e usos da mesma
CN108727347B (zh) * 2017-04-14 2020-06-16 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
CN115124520A (zh) * 2017-07-04 2022-09-30 四川海思科制药有限公司 阿片受体激动剂及其应用
WO2019052557A1 (zh) 2017-09-18 2019-03-21 上海华汇拓医药科技有限公司 μ-阿片受体激动剂及其制备方法和在医药领域的应用
MX395589B (es) * 2017-09-28 2025-03-25 Jiangsu Hengrui Medicine Co Método para preparar derivado de oxaespirociclo e intermediario del mismo.
CN111148515B (zh) * 2017-10-13 2022-07-19 山东绿叶制药有限公司 2,6-二氧杂螺[4,5]癸烷类衍生物、其制备方法及其在医药上的应用
BR112020010429A2 (pt) 2017-12-06 2020-11-24 Jiangsu Hengrui Medicine Co., Ltd. uso de agonista de kor em combinação com agonista de mor na preparação de fármaco para tratamento da dor
CN111836807A (zh) * 2018-04-28 2020-10-27 四川科伦博泰生物医药股份有限公司 氧杂螺环类化合物及其制备方法和用途
CN108424372B (zh) * 2018-05-11 2021-08-10 浙江华贝药业有限责任公司 2，2，2-三氟-n-[(s)-4-羰基四氢萘-1-基]-乙酰胺的纯化工艺
CN111163778B (zh) * 2018-05-14 2023-01-24 江苏恒瑞医药股份有限公司 一种mor受体激动剂药物组合物
CN108707086B (zh) * 2018-05-15 2021-08-10 浙江华贝药业有限责任公司 一种(1s，4s)-n-（4-羟基四氢萘-1-基）叔丁氧基碳酰胺的纯化工艺
WO2020073985A1 (zh) * 2018-10-12 2020-04-16 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
CN112638906B (zh) * 2018-10-12 2022-05-27 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
WO2020147848A1 (zh) * 2019-01-17 2020-07-23 上海海雁医药科技有限公司 三环取代的氧杂螺环衍生物、其制法与医药上的用途
CN111662284B (zh) * 2019-03-06 2021-08-10 上海海雁医药科技有限公司 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途
CN112789276B (zh) * 2019-08-14 2024-07-30 上海海雁医药科技有限公司 镇痛化合物、其制法与医药上的用途
CN114269751B (zh) * 2020-01-17 2024-04-16 上海海雁医药科技有限公司 光学纯的氧杂螺环取代的吡咯并吡唑衍生物、其制法与医药上的用途
KR102847070B1 (ko) * 2020-01-17 2025-08-14 상하이 하이옌 파마슈티컬 테크놀로지 컴퍼니, 리미티드 아자비시클릭 치환된 옥사스피로 유도체, 이의 제조 방법 및 의학적 용도
CN113214264B (zh) * 2020-01-21 2022-08-09 上海海雁医药科技有限公司 二氢吡咯并五元杂芳基取代的氧杂螺环衍生物、其制法与医药上的用途
CA3168260A1 (en) 2020-01-22 2021-07-29 Jiangsu Hengrui Medicine Co., Ltd. Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof
CN114075141B (zh) * 2020-08-20 2025-02-25 上海致根医药科技有限公司 阿片受体“偏向性”配体、其制备方法及其在医药上的应用
CN114539257B (zh) * 2020-11-24 2023-08-11 江苏恒瑞医药股份有限公司 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用
JP7751645B2 (ja) 2020-12-29 2025-10-08 上海海雁医薬科技有限公司 オキシスピロ環置換ピロロピラゾール誘導体及びその中間体並びにその調製方法
EP4361154A4 (en) * 2021-07-13 2025-06-18 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Pharmaceutically acceptable salt of a Mor receptor agonist, polymorph thereof, and use thereof
AU2022322838B2 (en) * 2021-08-02 2024-12-12 Jiangsu Nhwa Pharmaceutical Co., Ltd Oxaspiro derivative, and preparation method therefor and use thereof
CN117263956A (zh) * 2022-01-19 2023-12-22 天地恒一制药股份有限公司 阿片受体激动剂及其制备方法和用途
CN116589451B (zh) * 2022-02-11 2024-07-09 成都硕德药业有限公司 一种6-氧杂螺[4,5]癸烷类化合物的新晶型、用途及其制备方法
WO2024067542A1 (zh) * 2022-09-27 2024-04-04 上海枢境生物科技有限公司 一种含螺环类衍生物的盐、晶型及其制备方法和应用
CN120359196A (zh) 2023-01-18 2025-07-22 上海森辉医药有限公司 一种四氢-1-萘胺及其衍生物的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2160534B1 (es) 1999-12-30 2002-04-16 Vita Invest Sa Nuevos esteres derivados de (rr,ss)-2-hidroxibenzoato de 3-(2-dimetilaminometil-1-hidroxiciclohexil) fenilo.
DE10044649A1 (de) 2000-09-08 2002-07-04 Gruenenthal Gmbh Substituierte 4-Phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
US7999107B2 (en) * 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
US20090028873A1 (en) 2007-07-27 2009-01-29 Auspex Pharmaceuticals, Inc. Substituted cyclohexanols
WO2010051476A1 (en) 2008-10-31 2010-05-06 Pain Therapeutics, Inc. Filamin a-binding anti-inflammatory analgesic
CN102741258B (zh) 2009-06-17 2015-09-30 德州大学体系董事会 作为分离剂的环果聚糖的组成物及方法
PT3290415T (pt) 2011-03-23 2021-03-29 Trevena Inc Ligandos de recetores opioides e métodos de utilização e fabrico dos mesmos
ES2577861T3 (es) 2011-12-12 2016-07-19 Grünenthal GmbH Proceso para la preparación de (1R,4R)-6'-fluor-(N,N-dimetil- y N-metil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano-[3,4,b]indol]-4-amina
GB2519486A (en) 2012-08-03 2015-04-22 Johnson Matthey Plc A method for preparing oxycodone
CA2891334C (en) 2012-11-13 2021-10-19 Array Biopharma Inc. Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain

Also Published As

Publication number Publication date
RU2018115569A (ru) 2019-11-18
HUE048032T2 (hu) 2020-05-28
DK3354649T3 (da) 2020-02-24
KR102703513B1 (ko) 2024-09-06
TWI727981B (zh) 2021-05-21
RU2018115569A3 (es) 2020-01-20
PL3354649T3 (pl) 2020-07-27
RU2733373C2 (ru) 2020-10-01
CA3000761A1 (en) 2017-04-20
EP3354649B1 (en) 2019-12-04
CN107001347A (zh) 2017-08-01
JP6824502B2 (ja) 2021-02-03
BR112018006448A2 (pt) 2018-10-16
US10442793B2 (en) 2019-10-15
TW201718558A (zh) 2017-06-01
AU2016339404B2 (en) 2020-08-27
AU2016339404A1 (en) 2018-05-24
CN107001347B (zh) 2019-09-24
WO2017063509A1 (zh) 2017-04-20
PT3354649T (pt) 2020-02-03
EP3354649A4 (en) 2018-08-08
JP2018534257A (ja) 2018-11-22
US20180297988A1 (en) 2018-10-18
KR20180063251A (ko) 2018-06-11
EP3354649A1 (en) 2018-08-01
MX382815B (es) 2025-03-12
CA3000761C (en) 2024-02-13
ES2772689T3 (es) 2020-07-08

Similar Documents

Publication Publication Date Title
MX2018004175A (es) Derivado oxa espiro, su metodo de preparacion, y sus aplicaciones en medicinas.
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
MX2017014956A (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares.
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
NI201800133A (es) Nuevos derivados piperidinilo sustituidos con (hetero) arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
PE20151067A1 (es) Inhibidores de autotaxina
MX2017016376A (es) Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
CL2018001569A1 (es) Compuestos heteroaromáticos como inhibidores de btk
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
MX391031B (es) Derivados de diaril y arilheteroaril urea como moduladores del receptor de serotonina 5-ht2a útiles para la profilaxis y el tratamiento de alucinaciones asociadas con una enfermedad neurodegenerativa.
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
CR20160460A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
CL2022003703A1 (es) Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
CL2017000707A1 (es) Derivados de nucleosidos sustituidos de 4'-vinilo como inhibidores de la replicación del arn del virus sincicial respiratorio